| Ms Maria C Capobianco, MA | |
|
5530 Wisconsin Ave, Suite 1455, Chevy Chase, MD 20815-4404 | |
| (301) 656-8630 | |
| (301) 656-8631 |
| Full Name | Ms Maria C Capobianco |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 14 Years |
| Location | 5530 Wisconsin Ave, Chevy Chase, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215157268 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 00678 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chevy Chase Ent Associates, Llc | 0446286314 | 6 |
News Archive
Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.
The benefits of listening to music for patients on mechanical ventilation was revealed in a systematic review by a team of Cochrane researchers led by Drexel University College of Nursing and Health Professions associate professor Dr. Joke Bradt. The review found that listening to music may relax patients and potentially result in fewer complications.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
A new targeted drug delivery method, which combines two nanoparticles into one larger one, uses ultrasound to image tumors and release the anticancer drug doxorubicin from "nanobubbles" into the same tumors.
The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.
› Verified 6 days ago
| Provider Name | Chevy Chase Ent Associates, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497801039 PECOS PAC ID: 0446286314 Enrollment ID: O20050712000705 |
News Archive
Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.
The benefits of listening to music for patients on mechanical ventilation was revealed in a systematic review by a team of Cochrane researchers led by Drexel University College of Nursing and Health Professions associate professor Dr. Joke Bradt. The review found that listening to music may relax patients and potentially result in fewer complications.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
A new targeted drug delivery method, which combines two nanoparticles into one larger one, uses ultrasound to image tumors and release the anticancer drug doxorubicin from "nanobubbles" into the same tumors.
The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Maria C Capobianco, MA 300 Kimblewick Dr, Silver Spring, MD 20904-6318 Ph: (301) 622-5821 | Ms Maria C Capobianco, MA 5530 Wisconsin Ave, Suite 1455, Chevy Chase, MD 20815-4404 Ph: (301) 656-8630 |
News Archive
Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.
The benefits of listening to music for patients on mechanical ventilation was revealed in a systematic review by a team of Cochrane researchers led by Drexel University College of Nursing and Health Professions associate professor Dr. Joke Bradt. The review found that listening to music may relax patients and potentially result in fewer complications.
Delcath Systems, Inc. announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration for the New Drug Application for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.
A new targeted drug delivery method, which combines two nanoparticles into one larger one, uses ultrasound to image tumors and release the anticancer drug doxorubicin from "nanobubbles" into the same tumors.
The U.S. Food and Drug Administration today approved Pancreaze Delayed Release Capsules, a pancreatic enzyme product. It is the third such product to receive FDA approval.
› Verified 6 days ago
Dr. Gerry G. Haughey, AUD., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5454 Wisconsin Ave Ste 1540, Chevy Chase, MD 20815 Phone: 301-652-8847 Fax: 301-652-3751 | |
Dr. Lisa Ann Gebert, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5454 Wisconsin Ave Ste 1540, Chevy Chase, MD 20815 Phone: 301-652-8847 Fax: 301-652-3751 | |
Ms. Stacy Diane Morrison, M.A., CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5454 Wisconsin Ave, St 1535, Chevy Chase, MD 20815 Phone: 301-652-8847 | |
Miss Judith Naomi Grobstein, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5454 Wisconsin Ave, Suite 1535, Chevy Chase, MD 20815 Phone: 301-652-8847 Fax: 301-652-3751 | |
Dr. Mary M. Adams, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5530 Wisconsin Ave, Suite 1540, Chevy Chase, MD 20815 Phone: 301-907-0002 | |
Nehama Pluznik, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5530 Wisconsin Ave, 1540, Chevy Chase, MD 20815 Phone: 301-907-0002 |